Skip to main content

Table 2 Additional clinical information regarding lung function and BAL cell content

From: Elevated levels of FN1 and CCL2 in bronchoalveolar lavage fluid from sarcoidosis patients

Group

VC

FEV1

DLCO

Macrophages

Lymphocytes

Neutrophils

Eosinophils

CD4/CD8 ratio

N

[%]

N

[%]

N

[%]

N

[%]

N

[%]

N

[%]

N

[%]

N

 

Discovery

                

Asthma

17

107 (65–123)

17

103 (82–126)

0

NA

17

86 (70–95)

17

11 (4–26)

17

1.4 (0–5.4)

17

0.8 (0–13)

0

NA

Control

1

110 (110–110)

16

114 (86–130)

0

NA

16

88 (66–97)

16

7 (2–28)

16

1.8 (0–6.8)

16

0.2 (0–1.4)

13

2 (1–5)

Löfgren’s syndrome

12

88 (81–96)

12

90 (66–100)

10

95 (62–139)

18

74 (48–94)

18

22 (6–46)

18

1 (0–5.8)

18

0.1 (0–1.6)

18

8 (1–26)

Non-Löfgren’s syndrome

13

81 (66–104)

14

79 (48–104)

10

80 (53–128)

17

75 (42–97)

17

23 (3–58)

17

0.8 (0–15.2)

17

0 (0–1.2)

17

6 (2–25)

Verification

                

Control

9

108 (76–140)

14

106 (65–135)

0

NA

14

89 (60–96)

14

9 (3–39)

14

0.9 (0.4–2.2)

14

0 (0–0.6)

8

7 (1–37)

Löfgren’s syndrome

85

91 (57–118)

87

90 (52–120)

72

89 (56–126)

101

74 (34–98)

101

23 (2–65)

101

1 (0–14.4)

100

0.2 (0–13.3)

100

6 (1–33)

Non-Löfgren’s syndrome

80

86 (53–124)

87

87 (32–140)

59

87 (48–136)

96

75 (22–96)

96

23 (2–75)

96

1.4 (0–14.6)

96

0.2 (0–7.6)

94

5 (0–31)

  1. The number of individuals indicate the availability of data for the respective parameters. Data represented as median (minimum-maximum) unless stated otherwise
  2. VC vital capacity, FEV1 forced expiratory volume in one second, DLCO diffusion capacity of the lung for carbon monoxide, NA not analysed